The Liver Meeting® 2017 – DAA Era Linked with Better Liver Transplant Outcomes

Categories: Noticias

DAA Era Linked with Better Liver Transplant Outcomes
HCV treatment improvements reflected in graft, patient survival
by Michael Smith Michael Smith, North American Correspondent, MedPage Today
October 23, 2017
WASHINGTON — Patients with chronic hepatitis C have done better after liver transplant in the era of direct-acting agents (DAAs) against the virus, a researcher said here.

In a retrospective analysis of transplant outcomes, the DAA era was associated with a 36% drop in mortality a year after transplant, according to George Cholankeril, MD, of the University of Tennessee Health Science Center in Memphis.

“Historically, about a third of grafts were lost in patients who were transplanted with HCV [hepatitis C virus],” and patients needed another transplant, Charlton noted. If the proportion of failure falls, it means that more organs are available for other patients, he said.

Another benefit in the DAA era is that more patients with HCV are being cured before they reach the stage transplant stage, so “there’s less need.”

Author: Satot

Deja un comentario